Bergen, Norway, 27 January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the fourth quarter 2020 on Wednesday 10 February 2021. A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET.
The live webcast link will be available at www.bergenbio.com in the
Investors/Financial Reports section. A recording will be available shortly after the webcast has finished.
The fourth quarter report and presentation will be available on the Company’s website in the Investors/Financial Reports section from 7:00 am CET the same day.
